Displaying all 3 publications

Abstract:
Sort:
  1. C Thambiah S, Lai LC
    Pract Lab Med, 2021 Aug;26:e00248.
    PMID: 34368411 DOI: 10.1016/j.plabm.2021.e00248
    Diabetes mellitus (DM) is an escalating pandemic and an established cardiovascular risk factor. An important aspect of the interaction between DM and atherosclerotic cardiovascular disease (ASCVD) is diabetic dyslipidaemia, an atherogenic dyslipidaemia encompassing quantitative [hypertriglyceridaemia (hyperTG) and decreased high density lipoprotein cholesterol (HDL)] and qualitative [increased small dense low density lipoprotein cholesterol (sdLDL) particles, large very low density lipoprotein cholesterol (VLDL) subfraction (VLDL1) and dysfunctional HDL] modifications in lipoproteins. Much of the pathophysiology linking DM and dyslipidaemia has been elucidated. This paper aims to review the pathophysiology and management of diabetic dyslipidaemia with respect to ASCVD. Briefly, the influence of diabetic kidney disease on lipid profile and lipid changes causing type 2 diabetes mellitus are highlighted. Biomarkers of diabetic dyslipidaemia, including novel markers and clinical trials that have demonstrated that non-lipid and lipid lowering therapies can lower cardiovascular risk in diabetics are discussed. The stands of various international guidelines on lipid management in DM are emphasised. It is important to understand the underlying mechanisms of diabetic dyslipidaemia in order to develop new therapeutic strategies against dyslipidaemia and diabetes. The various international guidelines on lipid management can be used to tailor a holistic approach specific to each patient with diabetic dyslipidaemia.
  2. Mohammed Nawi A, Chin SF, Jamal R
    Pract Lab Med, 2020 Jan;18:e00142.
    PMID: 31720354 DOI: 10.1016/j.plabm.2019.e00142
    INTRODUCTION: In recent years, trace elements have gained importance as biomarkers in many chronic diseases. Unfortunately, the requirement for sample volume increases with the extent of investigation either for diagnosis or elucidating the mechanism of the disease. Here, we describe the method development and validation for simultaneous determination of 25 trace elements (lithium [Li], beryllium [Be], magnesium [Mg], aluminium [Al], vanadium [V], chromium [Cr], manganese [Mn], iron [Fe], cobalt [Co], nickel [Ni], copper [Cu], zinc [Zn], gallium [Ga], arsenic [As], selenium [Se], rubidium [Rb], strontium [Sr], silver [Ag], cadmium [Cd], caesium [Cs], barium [Ba], mercury [Hg], thallium [Tl], lead [Pb], uranium [U]) using only 20 μL of human serum.

    METHODS: Serum samples were digested with nitric acid and hydrochloric acid (ratio 1:1, v/v) and analysed by inductively coupled plasma-mass spectrometry (ICP-MS). Seronorm®, a human-derived serum control material was used as quality control samples.

    RESULTS: The coefficient of variations for both intra- and inter-day precisions were consistently <15% for all elements. The validated method was later tested on 30 human serum samples to evaluate its applicability.

    CONCLUSION: We have successfully developed and validated a precise and accurate analytical method for determining 25 trace elements requiring very low volume of human serum.

  3. Mobarak A, C Thambiah S, Masiman AD, Samsudin IN, Lai YY
    Pract Lab Med, 2024 May;40:e00395.
    PMID: 38707259 DOI: 10.1016/j.plabm.2024.e00395
    Acquired methemoglobinemia, predominantly due to oxidizing medications occurs when heme iron in hemoglobin is oxidized from ferrous to ferric ion and binds oxygen irreversibly leading to functional anemia, cyanosis, and tissue hypoxia. We report a case of a 60-year-old man with multiple comorbidities who was diagnosed with coronavirus disease 2019 (COVID-19) and developed methemoglobinemia after consumption of prescribed supplements. He presented with dyspnea and cyanosis. An oxygen saturation gap with characteristic chocolate-brown arterial blood indicated methemoglobinemia. Outsourced methemoglobin (MetHb) was increased at 9.0%. Despite aggressive intervention, he succumbed to his illness. In this case, we discuss the pathophysiology of why some individuals, especially the elderly with COVID-19 are more susceptible to develop methemoglobinemia after possibly being exposed to oxidizing agents. Laboratory methods for assessing oxygen saturation, including pulse oximetry, arterial blood gas and co-oximetry are examined in relation to this case. The importance of considering a diagnosis of methemoglobinemia based on clinical and biochemical findings although MetHb assay or co-oximetry are not readily available is also emphasized.
Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links